Though not often covered on BiotechDueDiligence, both abiraterone (ZYTIGA from $JNJ) and MDV-3100 (developed by Astellas and Medivation $MDVN) are key emerging players in the treatment landscape for prostate cancer. The late-breaking abstracts below related to these drugs caught my eye. Note that Oncogenex $OGXI has evaluated (or plans to) its clinical candidates custirsen (OGX-011) and OGX-427 in combination with these androgen receptor (AR) pathway-targeting therapies.
Add Comment
RSS Feed